ABL and RD-Biotech sign strategic partnership in cell and gene therapy GMP manufacturing

25 October 2022

Deal offers developers in cell and gene therapy streamlined access to plasmid DNA and viral vector manufacturing in new, flexible end-to-end service

Lyon and Besançon, France, October 25, 2022 – ABL, a pure play Contract Development and Manufacturing Organization (CDMO) with specialized expertise in the development and manufacturing of solutions for biopharma, including viruses for gene therapies, oncolytic viruses and vaccine candidates, and RD-Biotech, a CRO/CDMO providing custom services in development and production of plasmid DNA, monoclonal antibodies and recombinant proteins, today announce the signing of their exclusive strategic partnership in Cell and Gene Therapy (C&GT) GMP manufacturing. To know more